Page last updated: 2024-12-05

phenylglyoxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenylglyoxylic acid, also known as benzoylformic acid, is an organic compound with the formula C6H5COCO2H. It is a white solid that is soluble in water. Phenylglyoxylic acid is a versatile building block in organic synthesis and has been used in the preparation of a variety of compounds, including pharmaceuticals, agrochemicals, and polymers. It is also a precursor to mandelic acid, which is used in the treatment of urinary tract infections. Phenylglyoxylic acid is a substrate for the enzyme phenylglyoxylate decarboxylase, which is involved in the metabolism of phenylalanine. The compound is also a component of the melanin pigment and is thought to play a role in skin coloration. Studies on phenylglyoxylic acid focus on its potential in organic synthesis, its role in biological processes, and its applications in medicine and industry.'

phenylglyoxylic acid: styrene metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phenylglyoxylic acid : A 2-oxo monocarboxylic acid that is glyoxylic acid in which the aldehyde hydrogen is substituted by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11915
CHEMBL ID950
CHEBI ID18280
SCHEMBL ID38943
MeSH IDM0059539

Synonyms (82)

Synonym
CHEBI:18280 ,
benzoyl-formic acid
alpha-ketophenylacetic acid
benzeneacetic acid, .alpha.-oxo-
2-phenylethanoic acid
phenylglyoxalate
formic acid, benzoyl-
nsc-28293
oxophenylacetic acid
nsc28293
wln: qvvr
phenylgloxylic acid
2-oxo-2-phenylacetic acid
glyoxylic acid, phenyl-
benzeneglyoxylic acid
.alpha.-ketophenylacetic acid
AH-034/32845038
alpha-oxobenzeneacetic acid
phenyloxoacetic acid
brn 0606718
ai3-26708
nsc 28293
einecs 210-278-7
acetic acid,oxo,phenyl (phenylglyoxylic acid)
oxo(phenyl)acetic acid
benzeneacetic acid, alpha-oxo-
inchi=1/c8h6o3/c9-7(8(10)11)6-4-2-1-3-5-6/h1-5h,(h,10,11
phenylglyoxylate ,
2-oxo-2-phenylacetate
C02137
611-73-4
alpha-oxo-benzeneacetic acid
phenylglyoxylic acid
benzoylformic acid
benzoylformate
phenylglyoxylic acid, 97%
DB02279
b1129 ,
CHEMBL950 ,
benzoyl formic acid
bdbm50102174
benzeneacetic acid, alpha-oxo- (9ci)
BMSE000743
glyoxylic acid, phenyl- (8ci)
AKOS009158910
phenylglyoxalic acid
4-10-00-02737 (beilstein handbook reference)
2pzl5a0w0m ,
unii-2pzl5a0w0m
FT-0622758
AM20040854
S11007
.alpha.-oxobenzeneacetic acid
glycopyrronium bromide impurity b [ep impurity]
2-oxo-2-phenylethanoic acid
S6053
SCHEMBL38943
2-oxo-2-phenyl-acetic acid
phenyl glyoxalic acid
alpha-oxophenylacetic acid
hpgo
oxo-phenyl-acetic acid
phenyl glyoxylic acid
W-105187
DTXSID80209993
mfcd00002575
a-oxophenylacetic acid
phenylglyoxylic acid, purum, >=98.0% (t)
a-ketophenylacetic acid
a-oxobenzeneacetic acid
oxophenylacetic acid (benzoylformic acid)
glycopyrronium bromide imp. b (ep); oxophenylacetic acid; benzoylformic acid; glycopyrronium bromide impurity b; glycopyrronium impurity b
F0001-1606
HY-W010255
SY004129
AS-11992
Q663909
benzeneacetic acid, a-oxo-
CS-W010971
EN300-81664
2-oxo-2-phenylaceticacid
Z381360894

Research Excerpts

Dosage Studied

Male Wistar rats were dosed with 0, 1250, 3750 or 5000 mg/l of phenylglyoxylic acid (PGA) striatal concentration of dopamine (DA), norepinephrine (NE), and homovanillic acid (HVA) assessed in adult male rabbits exposed to styrene vapours.

ExcerptRelevanceReference
"The striatal concentration of dopamine (DA), norepinephrine (NE), and homovanillic acid (HVA) was assessed in adult male rabbits exposed to styrene vapours or dosed with mandelic acid (MA), phenylglyoxylic acid (PGA) and phenylglycine (PG)."( Styrene metabolism and striatal dopamine depletion in rabbits.
Falzoi, M; Franchini, I; Lucertini, S; Mutti, A; Romanelli, A, 1985
)
0.46
"Male Wistar rats were dosed intraperitoneally with styrene (400 mg/kg)."( The evidence for conjugated mandelic and phenylglyoxylic acids in the urine of rats dosed with styrene.
Linhart, I; Mládková, I; Mráz, J; Smejkal, J; Weidenhoffer, Z, 1997
)
0.56
"Male Wistar rats were dosed with 0, 1250, 3750 or 5000 mg/l of phenylglyoxylic acid (PGA) (CAS no."( Toxicity of the styrene metabolite, phenylglyoxylic acid, in rats after three months' oral dosing.
Hansen, EV; Hass, U; Ladefoged, O; Lam, HR; Lund, SP; Ostergaard, G; Simonsen, L,
)
0.65
" All showed close dose-response relationship."( [A study on biomarkers of styrene].
Cheng, H; Shao, H; Shi, YK; Wang, XY; Zhang, MP, 2003
)
0.32
" Particularly no sufficient proof of dose-response relationship measured against parameters of current exposure (MA + PGA, styrene/blood) and of chronic exposure (cumulative and average life time exposure resp."( Occupational styrene exposure and hearing loss: a cohort study with repeated measurements.
Bruckner, T; Seeber, A; Triebig, G, 2009
)
0.35
" With few exceptions (at frequencies of 1,000 and 1,500 Hz) no dose-response relationship between threshold and exposure data was found."( Occupational styrene exposure and hearing loss: a cohort study with repeated measurements.
Bruckner, T; Seeber, A; Triebig, G, 2009
)
0.35
" Using an exposure period of 30 days and the vacous chewing movement (VCM) model as an expression of striatal-motor toxicity, we found that incremental PGA dosing (220-400 mg/kg) significantly increased VCMs up to day 25, but decreased to control levels shortly after reaching maximum dose."( The styrene metabolite, phenylglyoxylic acid, induces striatal-motor toxicity in the rat: influence of dose escalation/reduction over time.
Bergh, JJ; Harvey, BH; Heyer, N; Mienie, LJ; Terre'Blanche, G; van der Schyf, CJ, 2011
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
biomarkerA substance used as an indicator of a biological state.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)2,700.00000.00053.49849.7600AID164985
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIC-terminal-binding protein 2Homo sapiens (human)
positive regulation of retinoic acid receptor signaling pathwayC-terminal-binding protein 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIC-terminal-binding protein 2Homo sapiens (human)
negative regulation of cell population proliferationC-terminal-binding protein 2Homo sapiens (human)
viral genome replicationC-terminal-binding protein 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionC-terminal-binding protein 2Homo sapiens (human)
white fat cell differentiationC-terminal-binding protein 2Homo sapiens (human)
regulation of transcription by RNA polymerase IIC-terminal-binding protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
transcription corepressor bindingC-terminal-binding protein 2Homo sapiens (human)
transcription corepressor activityC-terminal-binding protein 2Homo sapiens (human)
protein bindingC-terminal-binding protein 2Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorC-terminal-binding protein 2Homo sapiens (human)
protein kinase bindingC-terminal-binding protein 2Homo sapiens (human)
protein-containing complex bindingC-terminal-binding protein 2Homo sapiens (human)
NAD bindingC-terminal-binding protein 2Homo sapiens (human)
DNA-binding transcription factor bindingC-terminal-binding protein 2Homo sapiens (human)
transcription coregulator bindingC-terminal-binding protein 2Homo sapiens (human)
transcription coactivator activityC-terminal-binding protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
nucleusC-terminal-binding protein 2Homo sapiens (human)
synapseC-terminal-binding protein 2Homo sapiens (human)
transcription repressor complexC-terminal-binding protein 2Homo sapiens (human)
nucleusC-terminal-binding protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID191943Percent Stimulation of pyruvate oxidation in rat diaphragm was measured at 2 mM concentration of DCA (dichloroacetic acid)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Promotion of carbohydrate oxidation in the heart by some phenylglyoxylic acids.
AID1298930Inhibition of recombinant His6-tagged CtBP2 (31 to 384 residues) (unknown origin) dehydrogenase activity expressed in Escherichia coli BL21-Codonplus (DE3)-RIL cells using MTOB as substrate after 15 mins by NADH consumption assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP).
AID1130306Inhibition of glycolic acid oxidase (unknown origin) assessed as enzyme-mediated reduction of NaDCIP by sodium glycolate after 1 to 3 mins by spectrophotometer analysis1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Quantitative structure-activity relationships involving the inhibition of glycolic acid oxidase by derivatives of glycolic and glyoxylic acids.
AID1597857Inhibition of Staphylococcus aureus pyruvate carboxylase expressed in Escherichia coli BL21(DE3) assessed as FVB-OAA adduct formation using pyruvate as substrate by Fast violet B assay2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors.
AID188648Pyruvate dehydrogenase activity in vivo was measured following subcutaneous administration of 1.2 mmol/kg1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Promotion of carbohydrate oxidation in the heart by some phenylglyoxylic acids.
AID191929Tested for pyruvate oxidation in rat diaphragm, measured as % conversion of [14C]pyruvate to 14CO2 at 2 mM concentration1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Promotion of carbohydrate oxidation in the heart by some phenylglyoxylic acids.
AID191928Tested for pyruvate oxidation in rat diaphragm, measured as % conversion of [14C]pyruvate to 14CO2 at 0.5 mM concentration of DCA (dichloroacetic acid)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Promotion of carbohydrate oxidation in the heart by some phenylglyoxylic acids.
AID164985Inhibitory activity against Yersinia Protein-tyrosine phosphatase 1B2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
alpha-Ketocarboxylic acid-based inhibitors of protein tyrosine phosphatases.
AID188645Pyruvate dehydrogenase active/ Pyruvate dehydrogenase total was measured by sc administering the DCA in rat at a dose of 1.2 mmol/kg1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Promotion of carbohydrate oxidation in the heart by some phenylglyoxylic acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (160)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (23.13)18.7374
1990's35 (21.88)18.2507
2000's45 (28.13)29.6817
2010's37 (23.13)24.3611
2020's6 (3.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.55 (24.57)
Research Supply Index5.18 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index55.38 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.15%)5.53%
Reviews4 (2.30%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other168 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]